Evidence map›Paper›PMID 42797313›Full record

ReviewPharmaceutics2026

Nuclear Medicine Tracers Targeting Tumor-Associated Macrophages.

Dai Shi, Wujian Mao, Yutao Xie, Pan Zhou, Minqiang Hu, Yuxia Liu, Dengfeng Cheng

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dai ShiDepartment of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201203, China.ORCID 0000-0003-3903-5713
Wujian MaoDepartment of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201203, China.ORCID 0000-0001-6665-7505
Yutao XieDepartment of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201203, China.ORCID 0009-0009-0592-1435
Pan ZhouDepartment of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201203, China.
Minqiang HuDepartment of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201203, China.
Yuxia LiuDepartment of Applied Chemistry, Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China.
Dengfeng ChengDepartment of Nuclear Medicine, Shanghai Clinical Research and Trial Center, Shanghai 201203, China.ORCID 0000-0003-2886-3273

Funding

National Natural Science Foundation of China 82172002 and 82472037
6 · The paper itself

Abstract

Malignant tumors are the second major disease threatening human health, and their early diagnosis can significantly improve patients' prognosis. [

Indexed as

nuclear medicine tracerPET imagingSPECT imagingtumor-associated macrophages

Identifiers

PMID42797313
PMCPMC13610531

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.